Literature DB >> 29609875

SOCS-mediated immunomodulation of natural killer cells.

Narelle Keating1, Sandra E Nicholson2.   

Abstract

Natural killer (NK) cells are innate immune cells with an intrinsic ability to detect and kill infected and cancerous cells. The success of therapies targeting immune checkpoints on CD8 cells has intensified interest in harnessing the cytolytic effector functions of NK cells for new cancer treatments. NK cell development, survival and effector activity is dependent on exposure to the cytokine interleukin (IL)-15. The suppressor of cytokine (SOCS) proteins (CIS; SOCS1-7) are important negative regulators of cytokine signaling, and both CIS and SOCS2 are reported to have roles in regulating NK cell responses. Their immunomodulatory effects on NK cells suggest that these SOCS proteins are promising targets that can potentially form the basis of novel cancer therapies. Here we discuss the role of NK cells in tumor immunity as well as review the role of the SOCS proteins in regulating IL-15 signaling and NK cell function.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CIS; Cancer; Immune checkpoints; NK cells; SOCS proteins; SOCS2

Mesh:

Substances:

Year:  2018        PMID: 29609875     DOI: 10.1016/j.cyto.2018.03.033

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  10 in total

1.  Chimeric Peptidomimetics of SOCS 3 Able to Interact with JAK2 as Anti-inflammatory Compounds.

Authors:  Sara La Manna; Laura Lopez-Sanz; Flavia Anna Mercurio; Sara Fortuna; Marilisa Leone; Carmen Gomez-Guerrero; Daniela Marasco
Journal:  ACS Med Chem Lett       Date:  2020-03-19       Impact factor: 4.345

2.  Chronic IL-15 Stimulation and Impaired mTOR Signaling and Metabolism in Natural Killer Cells During Acute Myeloid Leukemia.

Authors:  Berna Bou-Tayeh; Vladimir Laletin; Nassim Salem; Sylvaine Just-Landi; Joanna Fares; Raphael Leblanc; Marielle Balzano; Yann M Kerdiles; Ghislain Bidaut; Olivier Hérault; Daniel Olive; Michel Aurrand-Lions; Thierry Walzer; Jacques A Nunès; Cyril Fauriat
Journal:  Front Immunol       Date:  2021-12-17       Impact factor: 7.561

3.  SSTP1, a Host Defense Peptide, Exploits the Immunomodulatory IL6 Pathway to Induce Apoptosis in Cancer Cells.

Authors:  Shyla Gopalakrishnan; Soumya Krishnan Uma; Gayathri Mohan; Amrutha Mohan; Geetha Shanmugam; Vineeth T V Kumar; Sreekumar J; Sivakumar K Chandrika; Dileep Vasudevan; Sai Ravi Chandra Nori; Shijulal Nelson Sathi; Sanil George; Tessy Thomas Maliekal
Journal:  Front Immunol       Date:  2021-11-19       Impact factor: 7.561

Review 4.  Engineered human pluripotent stem cell-derived natural killer cells: the next frontier for cancer immunotherapy.

Authors:  Huang Zhu; Dan S Kaufman
Journal:  Blood Sci       Date:  2019-09-17

5.  Suppressors of Cytokine Signaling Are Decreased in Major Depressive Disorder Patients.

Authors:  Nobuyuki Kobayashi; Shunichiro Shinagawa; Tomoyuki Nagata; Masahiro Shigeta; Kazuhiro Kondo
Journal:  J Pers Med       Date:  2022-06-25

6.  Genomic evidence of adaptive evolution in the reptilian SOCS gene family.

Authors:  Tian Xia; Lei Zhang; Guolei Sun; Xiufeng Yang; Honghai Zhang
Journal:  PeerJ       Date:  2021-06-24       Impact factor: 2.984

7.  Impaired Interleukin-18 Signaling in Natural Killer Cells From Patients With Systemic Juvenile Idiopathic Arthritis.

Authors:  Takashi Ohya; Kenichi Nishimura; Ayako Murase; Seira Hattori; Asami Ohara; Tomo Nozawa; Ryoki Hara; Shuichi Ito
Journal:  ACR Open Rheumatol       Date:  2022-03-11

Review 8.  Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.

Authors:  Nayoung Kim; Hun Sik Kim
Journal:  Front Immunol       Date:  2018-09-10       Impact factor: 7.561

Review 9.  JAK/STAT Cytokine Signaling at the Crossroad of NK Cell Development and Maturation.

Authors:  Dagmar Gotthardt; Jana Trifinopoulos; Veronika Sexl; Eva Maria Putz
Journal:  Front Immunol       Date:  2019-11-12       Impact factor: 7.561

10.  The role of accelerated growth plate fusion in the absence of SOCS2 on osteoarthritis vulnerability.

Authors:  Hasmik Jasmine Samvelyan; Carmen Huesa; Lin Cui; Colin Farquharson; Katherine Ann Staines
Journal:  Bone Joint Res       Date:  2022-03       Impact factor: 5.853

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.